In the news

9 January 2020
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Pharmaceutical Executive

12 November 2019
Pharma Panel Grapples With Drug Pricing, Real-World Evidence, and Creating Headroom for Innovative Therapies
Center for Biosimilars

5 September 2019
Insurers Pitch New Ways to Pay for Million-Dollar Therapies
Wall Street Journal

August 2019
Unlocking market access for gene therapies in the United States
McKinsey Insights

23 July 2019
A Need for Precision Financing Methods for Precision Medicines
Going Below the Surface (National Pharmaceutical Council)

15 July 2019
Paying for high-cost drugs like you’d pay a mortgage–and with strings attached
Managed Care

June 2019
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

18 June 2019
MIT Group Brings Together Stakeholders to Brainstorm How to Pay for Curative Therapies Over Time
American Journal of Managed Care

3 June 2019
Sticker Shock From Breakthrough Therapies Pressures Medicare
Bloomberg Law (registration required)

The Effective Medicaid Pharmacy Program: A White Paper for Medicaid Directors and State Agency Personnel
NESCSO

23 May 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
American Journal of Managed Care

17 May 2019
Gene Therapies Force Payment Innovation
Specialty Pharmacy Continuum

17 May 2019
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC

22 April 2019
When a Treatment Costs $450,000 or More, It Had Better Work
The Atlantic

15 April 2019
Biologics Are Natural Monopolies (Part 1): Why Biosimilars Do Not Create Effective Competition
Biologics Are Natural Monopolies (Part 2): A Proposal For Post- Exclusivity Price Regulation Of Biologics
Health Affairs

15 April 2019
Peter Bach’s latest crazy idea: Give up on biosimilars. Regulate drug prices instead
STAT News

4 April 2019
Value-based agreements could disrupt how we pay for new therapies
STAT News

19 February 2019
Paying for Cures: Ensuring Patient Access and System Sustainability
National Pharmaceutical Council E.V.I.dently Today

19 February 2019
Annuity Payment Model For Cures May Get Test Drive In Massachusetts
Pink Sheet

13 February 2019
Examining New Payment Ideas for Curative Therapies
American Journal of Managed Care

12 February 2019
MIT Releases New Policy and Practice Suggestions to Make Cures Accessible and Sustainable
NEWDIGS Initiative at MIT

12 February 2019
Preparing Patients and the Health System for Curative Therapies in the Pipeline
American Journal of Managed Care

1 February 2019
Focusing on Cures: Payers, Manufacturers, Patients and Academics Are Piloting Financing Options for Curative Therapies
BioCentury

27 January 2019
Precision Financing of Durable, Potentially Curative Therapies
Pharmaceutical Executive

10 January 2019
Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs
Washington Post

8 January 2019
Biotech Proposes Paying for Pricey Drugs by Installment
Wall Street Journal

19 December 2018
Are Orphan Reinsurance and Benefit Managers the Future of Financing High-Cost Therapies?
AJMC In Focus Blog

20 November 2018
Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”
JAMA Network

14 November 2018
A Search For New Ways To Pay For Drugs That Cost A Mint
NPR

10 September 2018
Improving Management of Gene and Cell Therapies
Pharmaceutical Executive

4 September 2018
Innovating Payment Models For Gene Therapy
First Report Managed Care

Send feedback

We want to know what works for you, and what doesn't. Please share your thoughts with us!

Subscribe to news

Join our mailing list to keep up to date on Paying for Cures news and events.